Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer

被引:29
作者
Hofmann, R [1 ]
Lehmer, A [1 ]
Hartung, R [1 ]
Robrecht, C [1 ]
Buresch, M [1 ]
Grothe, F [1 ]
机构
[1] TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,DEPT MED STAT & EPIDEMIOL,W-8000 MUNICH,GERMANY
关键词
urokinase; plasminogen inactivators; kidney neoplasms; prognosis;
D O I
10.1016/S0022-5347(01)66328-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Urokinase type plasminogen activator and its inhibitor plasminogen activator inhibitor are associated with invasion and formation of metastases in tumors. In a prospective study urokinase and plasminogen activator inhibitor-1 content in renal cell cancer and benign renal tissue was correlated with the traditional prognostic factors of TNM staging and grading as well as ploidy and actual clinical outcome of the patients. Materials and Methods: A total of 152 patients, who underwent transperitoneal tumor nephrectomy for renal cell cancer, was followed for a mean of 23.9 months. Urokinase and plasminogen activator inhibitor-1 from the tumor tissue and corresponding benign renal tissue were quantified from detergent extracted tissue samples (1% triton-X-100 in TBS) and measured with an enzyme-linked immunosorbent assay. Results: Urokinase content correlated with the development of distant metastases (log rank 4.32, p = 0.037). Cutoff value was 0.84 ng./mg. A group of 11 patients were considered to be at high risk for metastases (9 events) based on urokinase greater than 0.84 ng./mg., while 94 patients were considered to be at low risk (5 events) with urokinase less than 0.84 ng./mg. Plasminogen activator inhibitor-1 significantly correlated with the prevalence of distant metastases (log rank 5.17, Mo, 10.04 versus M1, 23.79, p = 0.02) and the development of new metastases postoperatively (M0, 10.85 versus M1, 27.36, p = 0.001). Cutoff value was 12 ng./mg. protein. A group of 41 patients were considered at high risk for relapse (6) based on plasminogen activator inhibitor-1 greater than 12 ng./mg. protein compared to 55 patients with plasminogen activator inhibitor-1 less than 12 ng./mg. protein with only 1 relapse during followup. Conclusions: Plasminogen activator inhibitor-1, the specific inhibitor of urokinase is a strong and independent prognostic factor in predicting early relapse of renal cell carcinoma. High and low risk groups for disease-free survival can be discriminated by plasminogen activator inhibitor-1 antigen content in the tumor tissue.
引用
收藏
页码:858 / 862
页数:5
相关论文
共 21 条
[1]   RECEPTOR-MEDIATED INTERNALIZATION AND DEGRADATION OF UROKINASE IS CAUSED BY ITS SPECIFIC INHIBITOR PAI-1 [J].
CUBELLIS, MV ;
WUN, TC ;
BLASI, F .
EMBO JOURNAL, 1990, 9 (04) :1079-1085
[2]   ACCESSIBILITY OF RECEPTOR-BOUND UROKINASE TO TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR [J].
CUBELLIS, MV ;
ANDREASEN, P ;
RAGNO, P ;
MAYER, M ;
DANO, K ;
BLASI, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (13) :4828-4832
[3]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[4]  
DUFFY JM, 1992, FIBRINOLYSIS S, V4, P55
[5]   E-CADHERIN-MEDIATED CELL CELL-ADHESION PREVENTS INVASIVENESS OF HUMAN CARCINOMA-CELLS [J].
FRIXEN, UH ;
BEHRENS, J ;
SACHS, M ;
EBERLE, G ;
VOSS, B ;
WARDA, A ;
LOCHNER, D ;
BIRCHMEIER, W .
JOURNAL OF CELL BIOLOGY, 1991, 113 (01) :173-185
[6]   PROTEASE AND PLASMINOGEN-ACTIVATOR ACTIVITY IN HUMAN BLADDER-CARCINOMA [J].
GORELIK, U ;
LINDNER, A ;
MAYER, M .
BRITISH JOURNAL OF UROLOGY, 1990, 66 (02) :170-174
[7]  
HASUI Y, 1989, CANCER RES, V49, P1067
[8]   TESTING A SEQUENCE OF OBSERVATIONS FOR A SHIFT IN LOCATION [J].
HAWKINS, DM .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1977, 72 (357) :180-186
[9]  
HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662
[10]  
HOLLAS W, 1991, CANCER RES, V51, P3690